Skip to main content
The Egyptian Journal of Internal Medicine
Download PDF
  • Original article
  • Open access
  • Published:

Tumor necrosis factor-alpha and alpha-fetoprotein as biomarkers for diagnosis and follow-up of hepatocellular carcinoma before and after interventional therapy

The Egyptian Journal of Internal Medicine volume 31, pages 840–848 (2019)Cite this article

Abstract

Introduction

Up to 90% of the hepatocellular carcinoma (HCC) cases in Egypt were attributable to hepatitis C virus (HCV) infection. The absolute positive and negative markers for HCC are still deficient. Alpha-fetoprotein (AFP), the most widely used biomarker for early detection and clinical follow-up of patients with HCC, has a sensitivity and a specificity of 41–65% and 80–94%, respectively, even with low cutoff value at 20 ng/ ml. High plasma levels of tumor necrosis factor-alpha (TNF-α) are associated with some cancers, and it has an important central role in hepatocarcinogenesis and involved in cancer invasion with or without metastasis.

Aim

To evaluate the diagnostic accuracy of TNF-α versus AFP as biomarkers for detection of HCC on top of HCV-related cirrhosis and to assess treatment response by using TNF-α and AFP after locoregional intervention of HCC.

Patients and methods

A total of 27 normal control, 51 cirrhotic patients, and 69 cirrhotic patients with HCC were studied in two phases. Radiofrequency ablation and transarterial chemoembolization were done, and patients were followed up for response and tumor marker values.

Results

TNF-α in the diagnosis of Egyptian patients with HCC related to HCV cirrhosis had a sensitivity of 100% and a specificity of 94.1% at a cutoff value of more than or equal to 30 pg/ml. Moreover, more than or equal to 15.2% decrement is a good predictor of complete ablation versus partially or failed ablation with a sensitivity of 78.6%, a specificity of 83.3%, and overall accuracy of 80.77%.

Conclusion

Combined use of TNF-α in addition to AFP increases sensitivity and specificity for early diagnosis of HCC rather than the use of each tumor marker alone. Moreover, TNF-α could be a better noninvasive tumor marker than AFP for assessment of response after locoregional therapy of HCC.

References

  1. Waly Raphael S, Yangde Z, YuXiang C. Hepatocellular carcinoma: focus on different aspects of management. ISRN Oncology 2012; 2012:421673.

    Article  Google Scholar 

  2. Goldman R, Ressom HW, Abdel-Hamid M, et al. Candidate markers for the detection of hepatocellular carcinoma in low-molecular weight fraction of serum. Carcinogenesis 2007; 28:2149–2153.

    Article  CAS  Google Scholar 

  3. Mohamoud YA, Mumtaz GR, Riome S, et al. The epidemiology of hepatitis C virus in egypt: a systematic review and data synthesis. BMC Infect Dis 2013; 13:288.

    Article  Google Scholar 

  4. Malaguarnera G, Giordano M, Paladina I, et al. Serum markers of hepatocellular carcinoma. Dig Dis Sci 2010; 55:2744–2755.

    Article  CAS  Google Scholar 

  5. Behne T, Copur MS. Biomarkers for hepatocellular carcinoma. Int J Hepatol 2012; 2012:859076.

    Article  Google Scholar 

  6. Debruyne EN, Delanghe JR. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. Clin Chim Acta 2008; 395:19–26.

    Article  CAS  Google Scholar 

  7. El-Zayadi A-R, Badran HM, Barakat EM, et al. Hepatocellular carcinoma in Egypt: a single center study over a decade. World J Gastroenterol 2005; 11:5193.

    PubMed  PubMed Central  Google Scholar 

  8. Zhao YJ, Ju Q, Li GC. Tumor markers for hepatocellular carcinoma (review). Mol Clin Oncol 2013; 1:593–598.

    Article  CAS  Google Scholar 

  9. Turner MD, Nedjai B, Hurst T, et al. Cytokines and chemokines: at the crossroads of cell signalling and inflammatory disease. Biochim Biophy Acta 2014; 1843:2563–2582.

    Article  CAS  Google Scholar 

  10. Wang YY, Lo GH, Lai KH, et al. Increased serum concentrations of tumor necrosis factor-alpha are associated with disease progression and malnutrition in hepatocellular carcinoma. J Chin Med Assoc 2003; 66:593–598.

    PubMed  Google Scholar 

  11. Capece D, Fischietti M, Verzella D, et al. The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. BioMed Res Int 2013; 2012:187204.

    Google Scholar 

  12. Sabry HS, El-Hendy AAK, Mohammed HI, et al. Study of serum tumor necrosis factor-α in patients with liver cirrhosis. Menouf Med J 2015; 28:525.

    Article  Google Scholar 

  13. Wang H, Liu J, Hu X, et al. Prognostic and therapeutic values of tumor necrosis factor-alpha in hepatocellular carcinoma. Med Sci Monit 2016; 22:3694.

    Article  CAS  Google Scholar 

  14. Pugh R, Murray-Lyon I, Dawson J, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60:646–649.

    Article  CAS  Google Scholar 

  15. Yamakado K, Miyayama S, Hirota S, et al. Prognosis of patients with intermediate-stage hepatocellular carcinomas based on the Child-Pugh score: subclassifying the intermediate stage (Barcelona Clinic Liver Cancer stage B). Jap J Radiol 2014; 32:644–649.

    Article  Google Scholar 

  16. Huo TI, Wang YW, Yang YY, et al. Model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor and its correlation with portal pressure in patients with liver cirrhosis. Liver Int 2007; 27:498–506.

    Article  CAS  Google Scholar 

  17. Forner A, Reig ME, de Lope CR, et al. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010; 30:61–74.

    Article  CAS  Google Scholar 

  18. Chang L, Wang Y, Zhang J, et al. The best strategy for HCC patients at each BCLC stage: a network meta-analysis of observational studies. Oncotarget 2017; 8:20418.

    Article  Google Scholar 

  19. Prajapati H, Spivey J, Hanish S, et al. Mrecist and EASL responses at early time point by contrast-enhanced dynamic mri predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB-TACE). Ann Oncol 2012; 24:965–973.

    Article  Google Scholar 

  20. Poon D, Anderson BO, Chen LT, et al. Management of hepatocellular carcinoma in Asia: consensus statement from the asian oncology summit2009. Lancet Oncol 2009; 10:1111–1118.

    Article  Google Scholar 

  21. Zhu RX, Seto WK, Lai CL, et al. Epidemiology of hepatocellular carcinoma in the Asia-Pacific region. Gut Liver 2016; 10:332.

    Article  Google Scholar 

  22. Omar A, Abou-Alfa GK, Khairy A, et al. Risk factors for developing hepatocellular carcinoma in Egypt. Chin Clin Oncol 2013; 2:43.

    PubMed  Google Scholar 

  23. Shaker MK, Abdella HM, Khalifa MO, et al. Epidemiological characteristics of hepatocellular carcinoma in Egypt: a retrospective analysis of 1313 cases. Liver Int 2013; 33:1601–1606.

    Article  CAS  Google Scholar 

  24. Kelly SL, Bird TG. The evolution of the use of serum alpha-fetoprotein in Clinical Liver Cancer Surveillance. J Immunobiol 2016; 1:1000116.

    PubMed  PubMed Central  Google Scholar 

  25. Spengler U. Hepatocellular carcinoma : diagnosis, prognosis& therapy. In: Mauss, et al... Hepatology. 8th edition. 2018.

  26. Trevisani F, D’Intino PE, Morselli-Labate AM, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. Hepatology 2001; 34:570–575.

    Article  CAS  Google Scholar 

  27. Kim JU, Shariff MI, Crossey MM, et al. Hepatocellular carcinoma: review of disease and tumor biomarkers. World J Hepatol 2016; 8:471.

    Article  Google Scholar 

  28. Torzilli G, Minagawa M, Takayama T, et al. Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy. Hepatology 1999; 30:889–893.

    Article  CAS  Google Scholar 

  29. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001; 35:421–430.

    CAS  PubMed  Google Scholar 

  30. Elbedewy TA, El-Feky S, El Sheikh MA, et al. Serum levels of soluble fas and soluble fas ligand as markers for hepatocellular carcinoma in hepatitis C virus patients. Int J Adv Res 2014; 2:911–919.

    Google Scholar 

  31. Zakhary NI, El-Merzabani MM, El-Sawi NM, et al. Impact of different biochemical markers in serum of patients with benign and malignant liver diseases. J Adv Res 2011; 2:49–55.

    Article  Google Scholar 

  32. Gopal P, Yopp AC, Waljee AK, et al. Factors that affect accuracy of α-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2014; 12: 870–877.

    Article  CAS  Google Scholar 

  33. Mahdy KA, EL-Gendy SM, Mansour TM, et al. Preliminary studies on nitric oxide (NO), tumor necrosis factor alpha (TNF-α), intercellular adhesion molecule-1 (ICAM-1) and AFP levels in serum of Egyptian farmers infected with hepatitis B and C viruses and hepatocellular carcinoma (HCC) patients. J Egypt Nat Cancer Inst 2001; 13:157–165.

    Google Scholar 

  34. Moustafa M, Morsi M, Hussein A, et al. Evaluation of tumor necrosis factor-α (TNF-α), soluble p-selectin (sp-selectin), gamma-glutamyl transferase (GGT), glutathione s-transferase pi (GST-pi) and alpha-fetoprotein (AFP) in patients with hepatocellular carcinoma before and during chemotherapy. Turk J Cancer 2005; 35:5–11.

    Google Scholar 

  35. Abdou A, El-Houssieny M. Study of serum tumor necrosis factor-alpha (TNF-α) in chronic hepatitis c virus patients with or without hepatocellular carcinoma [MD thesis]. Alexandria: Alexandria University, Faculty of Medicine; 2007.

    Google Scholar 

  36. Zekri ARN, Ashour MSED, Hassan A, et al. Cytokine profile in egyptian hepatitis c virus genotype-4 in relation to liver disease progression. World J Gastroenterol 2005; 11:6624.

    Article  Google Scholar 

  37. Hammam O, Mahmoud O, Zahran M, et al. Tissue expression of TNF-α and VEGF in chronic liver disease and hepatocellular carcinoma. Med J Cairo Univ 2013; 81.

  38. Moura AS, Carmo RA, Teixeira AL, et al. Soluble inflammatory markers as predictors of hepatocellular damage and therapeutic response in chronic hepatitis c. Braz J Infect Dis 2009; 13:375–382.

    Article  CAS  Google Scholar 

  39. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557–2576.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Mansoura University, Mansoura, Egypt

    Amr Elrabat PhD, MD (Assistant Professor), Shahera Eletreby & Ahmed M. Ali Zaid

  2. Department of Clinical Pathology, Mansoura University, Mansoura, Egypt

    Mohammed H. Eldeen Zaghloul

Authors
  1. Amr Elrabat PhD, MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shahera Eletreby
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ahmed M. Ali Zaid
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mohammed H. Eldeen Zaghloul
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amr Elrabat PhD, MD.

Additional information

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Elrabat, A., Eletreby, S., Zaid, A.M.A. et al. Tumor necrosis factor-alpha and alpha-fetoprotein as biomarkers for diagnosis and follow-up of hepatocellular carcinoma before and after interventional therapy. Egypt J Intern Med 31, 840–848 (2019). https://doi.org/10.4103/ejim.ejim_73_19

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/ejim.ejim_73_19

Keywords